tradingkey.logo

Philochem Announces Licensing Of Oncoacp3, To Rayzebio, A Bristol-Myers Squibb Company, For A Potential Value Of Up To $1.35Bn Plus Royalties

ReutersJun 10, 2025 10:02 PM

- Philogen SpA PHIL.MI:

  • PHILOCHEM AG ANNOUNCES THE LICENSING OF WORLDWIDE RIGHTS TO ONCOACP3, A NOVEL RADIOPHARMACEUTICAL THERAPEUTIC AND DIAGNOSTIC AGENT TARGETING PROSTATE CANCER, TO RAYZEBIO, A BRISTOL-MYERS SQUIBB COMPANY, FOR A POTENTIAL VALUE OF UP TO $1.35BN PLUS ROYALTIES

  • PHILOGEN SPA - CONSIDERATION COMPOSED OF A $350M UP-FRONT PAYMENT

  • PHILOGEN SPA- CO WILL RECEIVE MID-SINGLE TO LOW DOUBLE-DIGIT ROYALTIES PAYABLE ON GLOBAL NET SALES OF THERAPEUTIC AND DIAGNOSTIC AGENTS OF ONCOACP3

  • PHILOGEN SPA - CONSIDERATION COMPOSED OF UP TO $1.0BN IN DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI